Novo Nordisk ties US peptide craze to Wegovy pill sales
Executives told the Financial Times that broad American interest in peptide therapies is lifting demand for the oral weight-loss drug.
MH
By Maren Holt · Senior Reporter, GLP-1
May 6 03:00 ETSource: Financial Times
The wire
- 01Novo Nordisk said US enthusiasm for peptides is helping sales of its Wegovy pill, according to the Financial Times.
- 02Company framing of a wider peptide market is notable for clinics and compounders whose patients arrive already familiar with injectable peptides.
- 03The claim is a company characterisation of demand rather than a measured market analysis, and no unit figures were attached to it.
From the source
Read at ft.comNovo Nordisk says US peptide craze boosting Wegovy weight-loss pill sales